May 20th 2024
In recognition of Skin Cancer Awareness Month, Dermatology Times is reviewing research and strides in skin cancer treatment over the last decade.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Body’s circadian rhythms affect skin stem cell regulation
October 22nd 2013New research suggests that the body’s internal clock and its circadian rhythms adjust the modulation of skin stem cells based on the time of day - and that disruption to this cycle can cause tissue aging and lead to predisposition to skin cancer.
AAD work groups aim to facilitate research within the specialty
September 1st 2013The American Academy of Dermatology (AAD) Council on Science and Research’s Research Agenda work group has identified three keys areas - pruritus, cutaneous oncology and performance measurement and outcomes - to target in the future for continuing research in the dermatology specialty.
Treating wild-type BRAF mutated melanoma poses challenges
August 1st 2013Various approaches are being initiated to treat wild-type, BRAF mutated melanoma, according to the director of the Melanoma Program and co-leader of the Signal Transduction Program at Vanderbilt-Ingram Cancer Center in Nashville, Tenn.
Targeted therapy, immunotherapy tackle metastatic melanoma
July 1st 2013There has been a rapid revolution in the treatment of metastatic melanoma since the identification of driver oncogenes such as BRAF and its mutations more than a decade ago, according to a clinical researcher at the Vanderbilt-Ingram Cancer Center, Nashville, Tenn.
Cutting-edge devices evaluate fine nuances of pigmented lesions
June 1st 2013New and cutting edge technologies are proving useful for clinical diagnosis and early detection of melanoma. Depending on the diagnostic tool used, clinicians can improve their assessment of suspicious lesions and better evaluate the fine nuances differentiating benign and malignant pigmented lesions.